Zodasiran

N/A

Report date: 2026/05/17 20:00:15
NME

Base Information

Drug NameZodasiran
Drug Alias NameARO-ANG3ARO-ANG33VSA-003 (Arrowhead Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAngiopoietin like 3 inhibitorsRNA interference
TargetsAngiopoietin like 3
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRoche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesVisirna Therapeutics (Suzhou) Co LtdVisirna Biotechnology (Shanghai) Co LtdArrowhead Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A